

## **NRBDO Statements on a National Pharmacare Program**

On September 15-16, 2018, the NRBDO member reps met in Vancouver and discussed the implications of a National Pharmacare Program, from the perspective of people with rare blood disorders.

During this meeting, two statements were agreed upon by the member reps, and currently comprise the whole of the NRBDO's position on pharmacare. As more information is revealed about what the National Pharmacare Program could look like, this position may be updated.

1. It is the NRBDO's position that all blood products continue to be distributed through Canadian Blood Services (CBS) and Héma Québec (H-Q), as is the current practice. Any National Pharmacare Program created should not include blood products.
2. It is also the NRBDO's position that drugs for the treatment of rare diseases require a separate national program, within the National Pharmacare Program.